GlassScriptPhysician profile
Robert Gutierrez
NPI 1528292398
$3,438.73
in general payments reported to CMS, 2019-2025
21 companies · $731 in 2025
The $731 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.96 · 2022: $180 · 2023: $632 · 2024: $1,855 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,217.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $477.05 | 2024 | Senza, Vyrsa V1 |
| Bayer Healthcare Pharmaceuticals INC. | $415.23 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $394.57 | 2024 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $335.28 | 2021-2024 | Arexvy, Shingrix |
| Novo Nordisk INC | $237.72 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.56 | 2024 | Jardiance |
| Amgen INC. | $215.74 | 2024-2025 | Repatha, Repatha |
| Genzyme Corporation | $132.33 | 2023 | |
| Phathom Pharmaceuticals, INC. | $125.01 | 2024 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $121.87 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $121.85 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.82 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $102.72 | 2024 | Fanapt |
| Neurocrine Biosciences, INC. | $99.99 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.87 | 2025 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $70.00 | 2023 | Austedo |
| Scilex Pharmaceuticals INC. | $57.87 | 2022 | |
| Lilly USA, LLC | $42.56 | 2021-2023 | Mounjaro |
| Abbvie INC. | $24.85 | 2024 | |
| Janssen Pharmaceuticals, INC | $22.57 | 2024 | Xarelto |
| Genentech USA, INC. | $5.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.